



# 2025 UPDATES IN CARE OF THE HEMATOLOGIC MALIGNANCIES PATIENT

with Proceedings from International Medical Meetings

A CME/CNE-accredited Conference

FRIDAY, JANUARY 17, 2025

## AGENDA

- 7:00 am**      **IN-PERSON:** Check In, Continental Breakfast, Visit Exhibits and Experts
- 7:45 am**      **VIRTUAL:** Log in to Virtual Conference
- 8:00 am**      **Welcome and Introductions**  
Edward A. Stadtmauer, MD | Activity Director  
Robert H. Vonderheide, MD, DPhil | Director, Abramson Cancer Center
- 8:10 am**      **Keynote Address: T Cell-Based Therapeutic Alternatives for B-Cell Lymphomas**  
Stephen J. Schuster, MD | Activity Co-Director
- Q&A Discussion**  
**MODERATOR:** Edward A. Stadtmauer, MD | Activity Director

## NEW THERAPIES AND CURRENT PATIENT MANAGEMENT OF LYMPHOMAS

**MODERATOR:** Sunita D. Nasta, MD, FACP

- 8:40 am**      **Sequencing New Therapies in Follicular Lymphoma**  
Jordan S. Carter, MD
- 8:55 am**      **Advances in CLL/SLL**  
Emily Tomasulo, DO, FACP
- 9:10 am**      **Updates in Management of Hodgkin Lymphoma**  
Jakub Svoboda, MD | Activity Co-Director
- 9:25 am**      **Therapeutic Advances in T-Cell Lymphomas**  
Stefan K. Barta, MD, MS, MRCPCUK
- 9:40 am**      **Novel Approaches to Managing Large B-Cell Lymphomas**  
Colin J. Thomas, MD

# 2025 UPDATES IN CARE OF THE HEMATOLOGIC MALIGNANCIES PATIENT

with Proceedings from International Medical Meetings

A CME/CNE-accredited Conference

**9:55 am**      **Evolving Treatment Strategies in Mantle Cell Lymphoma**  
Elise A. Chong, MD

**10:10 am**      **Panel Discussion**  
**MODERATOR:** Sunita D. Nasta, MD, FACP

**PANEL:**

Stefan K. Barta, MD, MS, MRCP(UK)

Jordan S. Carter, MD

Elise A. Chong, MD

Mitchell E. Hughes, PharmD, BCOP | Oncology Pharmacy

Danielle Land, MSN, CRNP

John P. Plastaras, MD, PhD | Radiation Oncology

Jakub Svoboda, MD

Colin J. Thomas, MD

Emily Tomasulo, DO, FACP

**10:50 am**      **Break and Visit Exhibits**

## **UPDATE IN BLOOD AND MARROW TRANSPLANTATION AND CELLULAR THERAPY**

**MODERATOR:** Nasheed M. Hossain, MD | Activity Co-Director

**11:05 am**      **Current and Future Immunotherapies of Acute Leukemias**  
Noelle V. Frey, MD, MSCE

**11:20 am**      **Cell Therapy Approaches for Autoimmune Disease**  
Nasheed M. Hossain, MD | Activity Co-Director

**11:35 am**      **Progress in GVHD Therapies**  
Pashna N. Munshi, MD

# 2025 UPDATES IN CARE OF THE HEMATOLOGIC MALIGNANCIES PATIENT

with Proceedings from International Medical Meetings

A CME/CNE-accredited Conference

11:50 am

**Panel Discussion**

**MODERATOR:** Nasheed M. Hossain, MD | Activity Co-Director

**PANEL:**

Nicholas K. Brown, PhD, F(ACHI) | Pathology & Laboratory Medicine

Pashna N. Munshi, MD

Linda M. Perry, MS, PA-C

John P. Plastaras, MD, PhD | Radiation Oncology

12:10 pm

**Lunch Break and Visit Exhibits**

## UPDATE ON PATIENT CARE TREATMENT STRATEGIES IN LEUKEMIA

**Moderator:** Catherine E. Lai, MD, MPH | Activity Co-Director

1:10 pm

**Emerging Treatment Options for AML**

Keith W. Pratz, MD

1:25 pm

**MDS Bone Marrow Failure Syndromes**

Daria V. Babushok, MD, PhD

1:40 pm

**Update in Myeloproliferative Neoplasms**

Elizabeth O. Hexner, MD, MSTR

1:55 pm

**Equal Access to Transplant: Mismatched Donors for Blood Cancers**

Shannon R. McCurdy, MD

2:10 pm

**Panel Discussion**

**MODERATOR:** Catherine E. Lai, MD, MPH | Activity Co-Director

**PANEL:**

Daria V. Babushok, MD, PhD

Alison Carulli, PharmD | Oncology Pharmacy

Shannon R. McCurdy, MD

Elizabeth O. Hexner, MD, MSTR

John P. Plastaras, MD, PhD | Radiation Oncology

Keith W. Pratz, MD

Elizabeth M. Umbro, CRNP



# 2025 UPDATES IN CARE OF THE HEMATOLOGIC MALIGNANCIES PATIENT

with Proceedings from International Medical Meetings

A CME/CNE-accredited Conference

## CONTROVERSIES AND UPDATE FOR PATIENT CARE IN MULTIPLE MYELOMA

**Moderator:** Edward A. Stadtmauer, MD | Activity Director

**2:35 pm** **Smoldering Myeloma and Amyloidosis**

Adam Waxman, MD, MS

**2:50 pm** **Initial Therapy for Multiple Myeloma Including Transplant**

Shivani Kapur, MD

**3:05 pm** **Role of Immunotherapy for Myeloma**

Adam D. Cohen, MD

**3:20 pm** **Investigational Therapies for Relapsed Myeloma**

Dan T. Vogl, MD, MSCE

**3:35 pm** **Panel Discussion**

**MODERATOR:** Edward A. Stadtmauer, MD | Activity Director

### PANEL:

Adam D. Cohen, MD

Shivani Kapur, MD

Oxana Megherea, PharmD, BCOP | Oncology Pharmacy

John P. Plastaras, MD, PhD | Radiation Oncology

Leah R. Power, MSN, CRNP

Dan T. Vogl, MD, MSCE

Adam Waxman, MD, MS

**4:00 PM** **Adjourn**

# 2025 UPDATES IN CARE OF THE HEMATOLOGIC MALIGNANCIES PATIENT

with Proceedings from International Medical Meetings

A CME/CNE-accredited Conference

## Post Conference Details

After the conference has concluded, all attendees will receive an email from Penn CME with instructions on how to complete the post-test, evaluation, claim credit and obtain a certificate. Look for the email the week after the conference.

If you missed the Pre-Test, you will still be eligible to obtain your certificate after you complete the Post-Test and Evaluation. A Certificate of Participation is available to attendees who are not physicians or nurses.

## Meeting Videos

Website: [PennMedicine.org/Abramson/BloodCME2025](https://PennMedicine.org/Abramson/BloodCME2025)

*\*Recordings from the meeting will be available Thursday, January 23, 2024, through February 2026.*

### Preliminary Data References

Please note that some of the studies reported in this CE activity may have been published as abstracts only and/or presented at a conference. In these cases, the references provided in individual presentations reflect that and will be easy for you to recognize. These data and conclusions are included because expert faculty found them to be potentially important scientific contributions but should be considered preliminary until published in a peer-reviewed journal.

## Overview

This course is a comprehensive review of hematologic malignancies focusing on research developments over the preceding year and their application to the patient care journey. Didactic presentations will include case discussion with Penn faculty and community experts. Activity format will provide significant opportunity for interaction with expert faculty and other attendees with the aim of implementing new standards of patient care. Participants will leave with up-to-date, practical information which will have immediate clinical application.

## Who Should Attend

This activity has been designed for hematologists, medical and radiation oncologists, primary care physicians, pathologists, hematology/oncology fellows, oncology nurses, oncology social workers, and other healthcare professionals involved in the treatment of patients with blood cancer.

# 2025 UPDATES IN CARE OF THE HEMATOLOGIC MALIGNANCIES PATIENT

with Proceedings from International Medical Meetings

A CME/CNE-accredited Conference

## Learning Objectives

At the completion of this course, participants should be able to:

- Evaluate evolving treatment strategies for mantle cell lymphoma.
- Explain equal access to transplant and the use of mismatched donors.
- Describe cell therapy approaches for autoimmune diseases.
- Analyze progress in GVHD therapies.
- Evaluate emerging treatment options for AML.
- Apply current management of MDS and bone marrow failure syndromes.
- Summarize updates in CML and myeloproliferative disease.
- Analyze current and future immunotherapies for acute leukemias (including CD33 CAR T-cell therapy).
- Explain current approaches to smoldering myeloma and amyloidosis.
- Review initial therapy for multiple myeloma, including the role of transplant.
- Evaluate the role of immunotherapy in myeloma treatment.
- Analyze investigational therapies for relapsed myeloma.

## Accreditation



In support of improving patient care, Penn Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

## Designation of Credit

**PHYSICIANS:** Penn Medicine designates this live activity for a maximum of 6.75 *AMA PRA Category 1 Credits™*. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

**NURSES:** The program awards 6.75 NCPD hours.



# 2025 UPDATES IN CARE OF THE HEMATOLOGIC MALIGNANCIES PATIENT

with Proceedings from International Medical Meetings

A CME/CNE-accredited Conference

## Penn Medicine Speakers

### Activity Director

#### **Edward A. Stadtmauer, MD**

Roseman, Tarte, Harrow, and Shaffer Families' President's Distinguished Professor  
Chief, Hematologic Malignancies Section  
Division of Hematology Oncology  
Co-Leader, Hematologic Malignancies Research Program  
Perelman School of Medicine at the University of Pennsylvania / Penn Medicine  
Philadelphia, PA, USA

### Activity Co-Directors

#### **Catherine E. Lai, MD, MPH**

Associate Professor of Medicine (Hematology  
Oncology)  
Physician Leader, Leukemia Clinical Research  
Unit  
Perelman School of Medicine at the University  
of Pennsylvania / Penn Medicine  
Philadelphia, PA, USA

#### **Nasheed M. Hossain, MD**

Assistant Professor of Medicine (Hematology  
Oncology)  
Perelman School of Medicine at the University  
of Pennsylvania / Penn Medicine  
Philadelphia, PA, USA

#### **Patricia Mangan, RN, MSN, CRNP, APRN-BC \***

Nurse Lead, Hematologic Malignancies  
Program  
Abramson Cancer Center  
Perelman School of Medicine at the University  
of Pennsylvania / Penn Medicine  
Philadelphia, PA, USA

#### **David L. Porter, MD**

Jodi Fisher Horowitz Professor of Leukemia  
Care Excellence  
Director, Cell Therapy and Transplant  
Abramson Cancer Center  
Perelman School of Medicine at the University  
of Pennsylvania / Penn Medicine  
Philadelphia, PA, USA

#### **Keith W. Pratz, MD**

Associate Professor of Medicine (Hematology  
Oncology)  
Director, Leukemia Program  
Perelman School of Medicine at the University  
of Pennsylvania / Penn Medicine  
Philadelphia, PA, USA

*\*Nurse Planner*

# 2025 UPDATES IN CARE OF THE HEMATOLOGIC MALIGNANCIES PATIENT

with Proceedings from International Medical Meetings

A CME/CNE-accredited Conference

**Stephen J. Schuster, MD**

Robert and Margarita Louis-Dreyfus Professor  
in Chronic Lymphocytic Leukemia and  
Lymphoma Clinical Care and Research  
Director, Lymphoma Program  
Director, Lymphoma Translational Research  
Perelman School of Medicine at the University  
of Pennsylvania / Penn Medicine  
Philadelphia, PA, USA

**Jakub Svoboda, MD**

Associate Professor of Medicine (Hematology  
Oncology)  
Perelman School of Medicine at the University  
of Pennsylvania / Penn Medicine  
Philadelphia, PA, USA

## Faculty

**Daria V. Babushok, MD, PhD**

Assistant Professor of Medicine (Hematology-Oncology)  
Assistant Professor of Medicine in Pediatrics  
Perelman School of Medicine at the University of Pennsylvania / Penn Medicine  
Philadelphia, PA, USA

**Stefan K. Barta, MD, MS, MRCPCUK**

Associate Professor of Medicine (Hematology Oncology)  
Director, T-Cell Lymphoma Program  
Executive Officer, AIDS Malignancy Consortium  
Perelman School of Medicine at the University of Pennsylvania / Penn Medicine  
Philadelphia, PA, USA

**Nicholas K. Brown, PhD, F(ACHI)**

Associate Professor of Clinical Pathology and Laboratory Medicine  
Associate Director, Histocompatibility Testing Laboratory  
Perelman School of Medicine at the University of Pennsylvania/ Penn Medicine,  
Philadelphia, PA, USA

**Jordan S. Carter, MD**

Assistant Professor of Medicine (Hematology Oncology)  
Perelman School of Medicine at the University of Pennsylvania / Penn Medicine  
Philadelphia, PA, USA



# 2025 UPDATES IN CARE OF THE HEMATOLOGIC MALIGNANCIES PATIENT

with Proceedings from International Medical Meetings

A CME/CNE-accredited Conference

**Alison Carulli, PharmD**

Hematology Oncology Clinical Pharmacist

Penn Medicine

Philadelphia, PA, USA

**Elise A. Chong, MD**

Assistant Professor of Medicine (Hematology Oncology)

Perelman School of Medicine at the University of Pennsylvania / Penn Medicine

Philadelphia, PA, USA

**Adam D. Cohen, MD**

Associate Professor of Medicine (Hematology Oncology)

Director, Myeloma Immunotherapy

Perelman School of Medicine at the University of Pennsylvania / Penn Medicine

Philadelphia, PA, USA

**Noelle V. Frey, MD, MSCE**

Constance and Sankey Williams Associate Professor (Hematology Oncology)

Director of Clinical Cellular Therapy, Cell and Transplant Therapy Program

Perelman School of Medicine at the University of Pennsylvania / Penn Medicine

Philadelphia, PA, USA

**Elizabeth O. Hexner, MD, MSTR**

Associate Professor of Medicine (Hematology Oncology)

Medical Director, Center for Cellular Immunotherapies

Perelman School of Medicine at the University of Pennsylvania / Penn Medicine

Philadelphia, PA, USA

**Mitchell E. Hughes, PharmD, BCOP**

Clinical Pharmacy Specialist (Hematology/Oncology/Cellular Therapy)

Lymphoma Program and Lymphoma Translational Research

Perelman Center for Advanced Medicine at the University of Pennsylvania / Penn Medicine

Philadelphia, PA USA

# **2025 UPDATES IN CARE OF THE HEMATOLOGIC MALIGNANCIES PATIENT**

with Proceedings from International Medical Meetings

A CME/CNE-accredited Conference

**Shivani Kapur, MD**

Assistant Professor of Medicine (Hematology Oncology)

Perelman School of Medicine at the University of Pennsylvania / Penn Medicine

Philadelphia, PA, USA

**Danielle Land, MSN, CRNP**

Nurse Practitioner (Hematology Oncology)

Abramson Cancer Center

University of Pennsylvania

Philadelphia, PA, USA

**Shannon R. McCurdy, MD**

Assistant Professor of Medicine (Hematology Oncology)

Perelman School of Medicine at the University of Pennsylvania / Penn Medicine

Philadelphia, PA, USA

**Oxana Megherea, PharmD, BCOP**

Clinical Pharmacy Specialist (Oncology)

Penn Medicine

Philadelphia, PA, USA

**Pashna N. Munshi, MD**

Associate Professor of Medicine (Hematology Oncology)

Perelman School of Medicine at the University of Pennsylvania / Penn Medicine

Philadelphia, PA, USA

**Sunita D. Nasta, MD**

Professor of Medicine (Hematology Oncology)

Chair, Clinical Trials Review Monitoring Committee

Chair, Penn Institutional Review Board Associate

Perelman School of Medicine at the University of Pennsylvania / Penn Medicine

Philadelphia, PA, USA

**Linda M. Perry, MS, PA-C**

Physician Assistant of Cellular Therapy and Transplant

Perelman School of Medicine at the University of Pennsylvania / Penn Medicine

Philadelphia, PA, USA

# 2025 UPDATES IN CARE OF THE HEMATOLOGIC MALIGNANCIES PATIENT

with Proceedings from International Medical Meetings

A CME/CNE-accredited Conference

**John P. Plastaras, MD, PhD**

Professor of Radiation Oncology

Chief, Gastrointestinal/Hematologic Service, Radiation Oncology

Vice Chair, Strategic Clinical Research, Radiation Oncology

Perelman School of Medicine at the University of Pennsylvania / Penn Medicine

Philadelphia, PA, USA

**Leah R. Power, MSN, CRNP**

Nurse Practitioner (Hematology Oncology)

Abramson Cancer Center

University of Pennsylvania

Philadelphia, PA, USA

**Colin J. Thomas, MD**

Assistant Professor of Medicine (Hematology-Oncology)

Perelman School of Medicine at the University of Pennsylvania / Penn Medicine

Philadelphia, PA, USA

**Emily Tomasulo, DO**

Assistant Professor of Medicine (Hematology Oncology)

Perelman School of Medicine at the University of Pennsylvania / Penn Medicine

Philadelphia, PA, USA

**Elizabeth Umbro, CRNP**

Nurse Practitioner (Hematology Oncology)

Abramson Cancer Center

University of Pennsylvania

Philadelphia, PA, USA

**Dan T. Vogl, MD, MSCE**

Associate Professor of Medicine (Hematology Oncology)

Perelman School of Medicine at the University of Pennsylvania / Penn Medicine

Philadelphia, PA, USA

**Robert H. Vonderheide, MD, DPhil**

Director, Abramson Cancer Center

John H. Glick Abramson Cancer Center's Director Professor

Vice Dean for Cancer Programs, Perelman School of Medicine



# 2025 UPDATES IN CARE OF THE HEMATOLOGIC MALIGNANCIES PATIENT

with Proceedings from International Medical Meetings

A CME/CNE-accredited Conference

Vice President for Cancer Programs, UPHS

Perelman School of Medicine at the University of Pennsylvania / Penn Medicine

Philadelphia, PA, USA

## Adam Waxman, MD

Assistant Professor of Medicine (Hematology Oncology)

Perelman School of Medicine at the University of Pennsylvania / Penn Medicine

Philadelphia, PA, USA

## Disclosure of Financial Relationships

Staff in the Office of Continuing Medical and Interprofessional Education (CMIE) (Bruce Brod, MD, MCHI, FAAD, Vaughn Wurst and Ansheai Spence-Jones), and the listed Planning Committee Members (Barbara Lopez, Hyacen Putmon, Jema Varnie and Gabrielle Thomas) have reported that they have no financial relationships with any ineligible companies related to the content of this educational activity.

The following faculty and planning committee (\*) members have disclosed that they have no financial relationships with any ineligible companies related to the content of this educational activity.

Daria Babushok, MD  
Alison Carulli, PharmD  
Nasheed Hossain, MD\*  
Shivani Kapur, MD

Shannon Mccurdy, MD  
John Plastaras, MD  
Leah Power, CRNP RN  
Elizabeth Umbro, CRNP, RN

Robert Vonderheide, MD  
Adam Waxman, MD

The following planning committee (\*) and faculty members have reported the listed financial relationships with ineligible companies related to the content of their presentations. All financial relationships have been mitigated.

## FACULTY NAME

Stefan Barta, MD

## DISCLOSURE(S)

Consulting Fee-Affirmed (Relationship has ended)| Advisor-Bristol-Myers Squibb (Relationship has ended)| Membership on Advisory Committees or Review Panels, Board Membership, etc.-Janssen Pharmaceuticals (J&J)| Consulting Fee-Seattle Genetics (Relationship has ended)| Honoraria-Acrotech| Consulting Fee-Daiichi Sankyo (Relationship has ended)| Honoraria-Kyowa Kirin| Advisor-SecuraBio (Relationship has ended)| Advisor-Citius (Relationship has ended)| Advisor-ONO Therapeutics (Relationship has ended)

# 2025 UPDATES IN CARE OF THE HEMATOLOGIC MALIGNANCIES PATIENT

with Proceedings from International Medical Meetings

A CME/CNE-accredited Conference

Nicholas Brown, PhD

Other: Travel, dining and lodging paid for to attend company-sponsored workshop.-Thermo Fisher Scientific|Other: Travel, dining and lodging paid for to attend company-sponsored workshop.-Immucor (Relationship has ended)

Jordan Carter, MD

Honoraria-Ipsen (Relationship has ended)

Elise Chong, MD

Consulting Fee-Beigene (Relationship has ended)|Consulting Fee-Astra Zeneca Pharmaceuticals (Relationship has ended)|Grant or research support-AbbVie, Inc.|Grant or research support-Genentech (Relationship has ended)|Grant or research support-CARGO|Grant or research support-Genmab|Consulting Fee-Genmab (Relationship has ended)|Grant or research support-Nurix|Grant or research support-Astra Zeneca Pharmaceuticals

Adam Cohen, MD

Membership on Advisory Committees or Review Panels, Board Membership, etc.-Janssen Pharmaceuticals (J&J)|Grant or research support-Janssen Pharmaceuticals (J&J)|Membership on Advisory Committees or Review Panels, Board Membership, etc.-Bristol-Myers Squibb|Membership on Advisory Committees or Review Panels, Board Membership, etc.-Astra Zeneca Pharmaceuticals |Membership on Advisory Committees or Review Panels, Board Membership, etc.-Genentech|Grant or research support-Genentech|Grant or research support-Glaxo Smith Kline|Membership on Advisory Committees or Review Panels, Board Membership, etc.-Glaxo Smith Kline|Grant or research support-Novartis (Advanced Health Media) (Relationship has ended)|Membership on Advisory Committees or Review Panels, Board Membership, etc.-Novartis (Advanced Health Media) |Membership on Advisory Committees or Review Panels, Board Membership, etc.-Ichnos |Membership on Advisory Committees or Review Panels, Board Membership, etc.-Pfizer, Inc. |Membership on Advisory Committees or Review Panels, Board Membership, etc.-AbbVie, Inc. |Membership on Advisory Committees or Review Panels, Board Membership, etc.-iTeos (Relationship has ended)|Membership on Advisory Committees or Review Panels, Board Membership, etc.-Sanofi Genzyme (Relationship has ended)|Membership on Advisory Committees or Review Panels, Board Membership, etc.-Regeneron Pharmaceuticals, Inc. (Relationship has ended)|Membership on Advisory Committees or Review Panels, Board Membership, etc.-Kite Pharma|Membership on Advisory Committees or Review Panels, Board Membership, etc.-Legend|Consulting Fee-Moderna

# 2025 UPDATES IN CARE OF THE HEMATOLOGIC MALIGNANCIES PATIENT

with Proceedings from International Medical Meetings

A CME/CNE-accredited Conference

Noelle Frey, MD

Consulting Fee-Kite Pharma (Relationship has ended)| Consulting Fee-Autolus (Relationship has ended)| Consulting Fee-Sana Biotechnology (Relationship has ended)

Elizabeth Hexner, MD

Membership on Advisory Committees or Review Panels, Board Membership, etc.-Blueprint Medicines| Advisor-Cabaletta Bio Inc| Advisor-Disc Medicine| Membership on Advisory Committees or Review Panels, Board Membership, etc.-American Board of Internal Medicine

Mitchell Hughes, RPH

Advisor-AbbVie, Inc. (Relationship has ended)| Grant or research support-Acerta\_HOPA (Relationship has ended)| Advisor-Karyopharm (Relationship has ended)| Advisor-Astra Zeneca Pharmaceuticals (Relationship has ended) - 06/21/2024

Catherine Lai, MD, MPH\*

Advisor-Genentech| Advisor-Rigel| Advisor-Taiho Oncology (Relationship has ended)| Advisor-AbbVie, Inc.| Advisor-Novartis (Relationship has ended)| Consulting Fee-Jazz Pharma (Relationship has ended)| Advisor-Pfizer, Inc. (Relationship has ended)| Consulting Fee-PDS Biotechnology| Consulting Fee-MacroGenics (Relationship has ended)| Consulting Fee-Astellas (Relationship has ended)| Speakers Bureau-Jazz Pharma (Relationship has ended)| Speakers Bureau-Astellas (Relationship has ended)| Honoraria-OncLive (Relationship has ended)| Honoraria-BioAscent (Relationship has ended)| Advisor-Daiichi (Relationship has ended)

Danielle Land, CRNP,RN

Speakers Bureau-Astra Zeneca Pharmaceuticals| Membership on Advisory Committees or Review Panels, Board Membership, etc.-Incyte Corporation (Relationship has ended)| Speakers Bureau-Janssen Pharmaceuticals (J&J) (Relationship has ended)| Membership on Advisory Committees or Review Panels, Board Membership, etc.-Janssen Pharmaceuticals (J&J) (Relationship has ended)

Patricia Mangan, CRNP\*

Honoraria-Janssen Pharmaceuticals (J&J)| Honoraria-Bristol-Myers Squibb

Oxana Megherea, PharmD

Advisor-BioLineRx

Pashna Munshi, MD

Consulting Fee-Incyte Corporation (Relationship has ended)| Speakers Bureau-Incyte Corporation (Relationship has ended)| Speakers Bureau-Gilead Sciences, Inc (Relationship has ended)



# 2025 UPDATES IN CARE OF THE HEMATOLOGIC MALIGNANCIES PATIENT

with Proceedings from International Medical Meetings

A CME/CNE-accredited Conference

Sunita Nasta, MD

Grant or research support-Genentech|Grant or research support-ONO pharmaceuticals|Advisor-Genmab|Grant or research support-ATARA|Grant or research support-Cairbou Biosciences|Grant or research support-ASTEX|Grant or research support-Takeda Pharmaceuticals|Grant or research support-AbbVie, Inc.|Membership on Advisory Committees or Review Panels, Board Membership, etc.-Merck & Co

Linda Perry, PA-C

Paid consultant-Kadmon |Speakers Bureau-Sanofi Genzyme|Paid consultant-Incyte Corporation|Speakers Bureau-Incyte Corporation

David Porter, MD\*

Stocks or stock options, excluding diversified mutual funds of a publicly traded company-Genentech|Honoraria-Novartis (Advanced Health Media) (Relationship has ended)|Honoraria-Bristol-Myers Squibb (Relationship has ended)|Honoraria-Gilead Sciences, Inc (Relationship has ended)|Grant or research support-Novartis (Advanced Health Media)|Royalties or Patent Beneficiary-Novartis (Advanced Health Media)|Royalties or Patent Beneficiary-Tmunity (Relationship has ended)|Honoraria-Wiley publishing|Honoraria-Am Society for Transplant and Cell Therapy|Membership on Advisory Committees or Review Panels, Board Membership, etc.-Angiocrine|Membership on Advisory Committees or Review Panels, Board Membership, etc.-Mirror Biologics|Honoraria-Capstan (Relationship has ended)|Consulting Fee-Sana Biotechnology|Stocks or stock options, excluding diversified mutual funds of a publicly traded company-Sana Biotechnologies|Honoraria-Verismo (Relationship has ended)

Keith Pratz, MD\*

Advisor-AbbVie, Inc.|Advisor-Bristol-Myers Squibb (Relationship has ended)|Advisor-Novartis / Amgen (Relationship has ended)|Advisor-Jazz Pharmaceuticals (Relationship has ended)|Advisor-Astellas (Relationship has ended)|Advisor-Astra Zeneca Pharmaceuticals (Relationship has ended)|Advisor-Roche (Relationship has ended)

Stephen Schuster, MD\*

Consulting Fee-Genentech|Consulting Fee-AstraZeneca|Consulting Fee-BeiGene (Relationship has ended)|Membership on Advisory Committees or Review Panels, Board Membership, etc.-Caribou Biosciences|Grant or research support-Genentech|Grant or research support-Genentech|Consulting Fee-Genmab|Consulting Fee-Janssen Pharmaceuticals (J&J)|Consulting Fee-Kite Pharma Consulting Fee-Novartis / Amgen|Membership on Advisory Committees or Review Panels, Board Membership, etc. Novartis / Amgen|Membership on Advisory Committees or Review Panels, Board Membership, etc.-Legend Biotech|Membership

# 2025 UPDATES IN CARE OF THE HEMATOLOGIC MALIGNANCIES PATIENT

with Proceedings from International Medical Meetings

A CME/CNE-accredited Conference

on Advisory Committees or Review Panels, Board Membership, etc.-Nordic  
Nanovector (Relationship has ended)| Consulting Fee-BioNTech| Consulting  
Fee-AbbVie| Advisor-Vittoria Bio

Edward Stadtmauer, MD\*

Grant or research support-AbbVie, Inc.| Consulting Fee-Glaxo Smith Kline  
(Relationship has ended)| Consulting Fee-Sanofi Genzyme (Relationship  
has ended)| Consulting Fee-Bristol-Myers Squibb (Relationship has  
ended)| Consulting Fee-Amgen (Relationship has ended)

Jakub Svoboda, MD\*

Grant or research support-Incyte Corporation| Consulting Fee-Incyte  
Corporation (Relationship has ended)| Grant or research support-Merck &  
Co (Relationship has ended)| Grant or research support-Pharmacyclics  
(Relationship has ended)| Consulting Fee-Bristol-Myers Squibb  
(Relationship has ended)| Grant or research support-Bristol-Myers  
Squibb| Grant or research support-TG Therapeutics (Relationship has  
ended)| Consulting Fee-Seattle Genetics (Relationship has ended)| Grant or  
research support-Seattle Genetics (Relationship has ended)| Consulting  
Fee-Astra Zeneca Pharmaceuticals| Grant or research support-Astra Zeneca  
Pharmaceuticals| Consulting Fee-Atara| Consulting Fee-Adaptive| Grant or  
research support-Adaptive (Relationship has ended)| Grant or research  
support-Gilead Sciences, Inc| Consulting Fee-Genmab (Relationship has  
ended)| Consulting Fee-AbbVie, Inc.| Consulting Fee-CRISPR (Relationship  
has ended)

Colin Thomas, MD

Membership on Advisory Committees or Review Panels, Board  
Membership, etc.-Acrotech (Relationship has ended)

Emily Tomasulo, DO

Consulting Fee-Astra Zeneca Pharmaceuticals (Relationship has ended)

Dan Vogl, MD

Consulting Fee-Takeda Pharmaceuticals (Relationship has  
ended)| Consulting Fee-Janssen Pharmaceuticals (J&J) (Relationship has  
ended)| Consulting Fee-Glaxo Smith Kline (Relationship has  
ended)| Consulting Fee-Karyopharm (Relationship has ended)| Grant or  
research support-Takeda Pharmaceuticals (Relationship has ended)| Grant  
or research support-Active Biotech| Consulting Fee-CSL Behring  
(Relationship has ended)| Consulting Fee-Sanofi Genzyme (Relationship  
has ended)| Consulting Fee-Genentech (Relationship has  
ended)| Consulting Fee-AbbVie, Inc. (Relationship has ended)| Consulting  
Fee-Bristol-Myers Squibb (Relationship has ended)

# 2025 UPDATES IN CARE OF THE HEMATOLOGIC MALIGNANCIES PATIENT

with Proceedings from International Medical Meetings

A CME/CNE-accredited Conference

## Thank you to Our Exhibitors

AbbVie

Acrotech Biopharma

Adaptive Biotechnologies

ADC Therapeutics

Alexion Pharmaceuticals

Amgen

Apellis Pharmaceuticals

Astellas

AstraZeneca

Autolus

BeiGene

Blueprint Medicines

Bristol Myers Squibb - CAR-T

Bristol Myers Squibb -

Hematology

Daiichi Sankyo

Genentech

Genmab

Geron

GSK

Incyte

Invivyd

Ipsen

Johnson and Johnson

Innovative Medicine

Karyopharm Therapeutics

Kite, A Gilead Company

Kyowa Kirin

Legend Biotech

The Leukemia & Lymphoma

Society

Loxo@Lilly

Merck

Pfizer Oncology

Pharmacyclics LLC, An AbbVie

Company

PharmaEssentia

Rigel Pharmaceuticals

Sanofi

Secura Bio

SERB Pharmaceuticals

Servier Pharmaceuticals

Sobi

Syndax Pharmaceuticals

Taiho Oncology

Takeda Oncology